A phase II trial of high dose epirubicin in patients with advanced breast carcinoma

Kathy Miller, Nikhil Munshi, David Loesch, Lawrence Einhorn, George W. Sledge

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

BACKGROUND. Anthracyclines are among the most active drugs in the treatment of breast carcinoma and exhibit a steep dose-response curve in vitro. This trial was performed to determine the efficacy and toxicity of epirubicin in the treatment of patients with advanced breast carcinoma when administered as a single agent in maximal doses. METHODS. Patients with chemotherapy-naive American Joint Committee on Cancer/International Union Against Cancer Stage IIIB or IV breast carcinoma received epirubicin, 180 mg/m2, intravenously every 3 weeks for a maximum of 8 cycles of therapy, Hematopoietic growth factors and cardioprotective agents were not used routinely. RESULTS. Twenty-seven patients were entered in the study. Although NCl/CTC criteria Grade 4 neutropenia occurred in 96% of patients, epirubicin was administered at 83.1% of the planned dose intensity. The median fall in left ventricular ejection fraction was 10%; clinical cardiac toxicity was observed in 3 patients. Objective responses were observed in 21 patients, including 6 complete responses. CONCLUSIONS. High dose epirubicin was found to result in substantial hematologic toxicity but was highly active in the treatment of patients with advanced breast carcinoma.

Original languageEnglish
Pages (from-to)375-380
Number of pages6
JournalCancer
Volume88
Issue number2
DOIs
StatePublished - Jan 15 2000

Fingerprint

Epirubicin
Breast Neoplasms
Cardiotonic Agents
Anthracyclines
Therapeutics
Neutropenia
Stroke Volume
Intercellular Signaling Peptides and Proteins
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Anthracycline
  • Breast carcinoma
  • Chemotherapy
  • Dose intensity
  • Epirubicin
  • Metastatic

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A phase II trial of high dose epirubicin in patients with advanced breast carcinoma. / Miller, Kathy; Munshi, Nikhil; Loesch, David; Einhorn, Lawrence; Sledge, George W.

In: Cancer, Vol. 88, No. 2, 15.01.2000, p. 375-380.

Research output: Contribution to journalArticle

Miller, Kathy ; Munshi, Nikhil ; Loesch, David ; Einhorn, Lawrence ; Sledge, George W. / A phase II trial of high dose epirubicin in patients with advanced breast carcinoma. In: Cancer. 2000 ; Vol. 88, No. 2. pp. 375-380.
@article{07afa9195c1644fba5fdb873e8a97a66,
title = "A phase II trial of high dose epirubicin in patients with advanced breast carcinoma",
abstract = "BACKGROUND. Anthracyclines are among the most active drugs in the treatment of breast carcinoma and exhibit a steep dose-response curve in vitro. This trial was performed to determine the efficacy and toxicity of epirubicin in the treatment of patients with advanced breast carcinoma when administered as a single agent in maximal doses. METHODS. Patients with chemotherapy-naive American Joint Committee on Cancer/International Union Against Cancer Stage IIIB or IV breast carcinoma received epirubicin, 180 mg/m2, intravenously every 3 weeks for a maximum of 8 cycles of therapy, Hematopoietic growth factors and cardioprotective agents were not used routinely. RESULTS. Twenty-seven patients were entered in the study. Although NCl/CTC criteria Grade 4 neutropenia occurred in 96{\%} of patients, epirubicin was administered at 83.1{\%} of the planned dose intensity. The median fall in left ventricular ejection fraction was 10{\%}; clinical cardiac toxicity was observed in 3 patients. Objective responses were observed in 21 patients, including 6 complete responses. CONCLUSIONS. High dose epirubicin was found to result in substantial hematologic toxicity but was highly active in the treatment of patients with advanced breast carcinoma.",
keywords = "Anthracycline, Breast carcinoma, Chemotherapy, Dose intensity, Epirubicin, Metastatic",
author = "Kathy Miller and Nikhil Munshi and David Loesch and Lawrence Einhorn and Sledge, {George W.}",
year = "2000",
month = "1",
day = "15",
doi = "10.1002/(SICI)1097-0142(20000115)88:2<375::AID-CNCR19>3.0.CO;2-M",
language = "English",
volume = "88",
pages = "375--380",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - A phase II trial of high dose epirubicin in patients with advanced breast carcinoma

AU - Miller, Kathy

AU - Munshi, Nikhil

AU - Loesch, David

AU - Einhorn, Lawrence

AU - Sledge, George W.

PY - 2000/1/15

Y1 - 2000/1/15

N2 - BACKGROUND. Anthracyclines are among the most active drugs in the treatment of breast carcinoma and exhibit a steep dose-response curve in vitro. This trial was performed to determine the efficacy and toxicity of epirubicin in the treatment of patients with advanced breast carcinoma when administered as a single agent in maximal doses. METHODS. Patients with chemotherapy-naive American Joint Committee on Cancer/International Union Against Cancer Stage IIIB or IV breast carcinoma received epirubicin, 180 mg/m2, intravenously every 3 weeks for a maximum of 8 cycles of therapy, Hematopoietic growth factors and cardioprotective agents were not used routinely. RESULTS. Twenty-seven patients were entered in the study. Although NCl/CTC criteria Grade 4 neutropenia occurred in 96% of patients, epirubicin was administered at 83.1% of the planned dose intensity. The median fall in left ventricular ejection fraction was 10%; clinical cardiac toxicity was observed in 3 patients. Objective responses were observed in 21 patients, including 6 complete responses. CONCLUSIONS. High dose epirubicin was found to result in substantial hematologic toxicity but was highly active in the treatment of patients with advanced breast carcinoma.

AB - BACKGROUND. Anthracyclines are among the most active drugs in the treatment of breast carcinoma and exhibit a steep dose-response curve in vitro. This trial was performed to determine the efficacy and toxicity of epirubicin in the treatment of patients with advanced breast carcinoma when administered as a single agent in maximal doses. METHODS. Patients with chemotherapy-naive American Joint Committee on Cancer/International Union Against Cancer Stage IIIB or IV breast carcinoma received epirubicin, 180 mg/m2, intravenously every 3 weeks for a maximum of 8 cycles of therapy, Hematopoietic growth factors and cardioprotective agents were not used routinely. RESULTS. Twenty-seven patients were entered in the study. Although NCl/CTC criteria Grade 4 neutropenia occurred in 96% of patients, epirubicin was administered at 83.1% of the planned dose intensity. The median fall in left ventricular ejection fraction was 10%; clinical cardiac toxicity was observed in 3 patients. Objective responses were observed in 21 patients, including 6 complete responses. CONCLUSIONS. High dose epirubicin was found to result in substantial hematologic toxicity but was highly active in the treatment of patients with advanced breast carcinoma.

KW - Anthracycline

KW - Breast carcinoma

KW - Chemotherapy

KW - Dose intensity

KW - Epirubicin

KW - Metastatic

UR - http://www.scopus.com/inward/record.url?scp=0034650720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034650720&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(20000115)88:2<375::AID-CNCR19>3.0.CO;2-M

DO - 10.1002/(SICI)1097-0142(20000115)88:2<375::AID-CNCR19>3.0.CO;2-M

M3 - Article

C2 - 10640971

AN - SCOPUS:0034650720

VL - 88

SP - 375

EP - 380

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -